News coverage about NxStage Medical (NASDAQ:NXTM) has trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NxStage Medical earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 47.0041525889663 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of NxStage Medical (NXTM) traded down 0.36% during midday trading on Monday, reaching $27.78. 100,601 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $27.02 and its 200 day moving average price is $25.95. The company’s market cap is $1.83 billion. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The business had revenue of $92.20 million during the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the previous year, the business posted ($0.03) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts anticipate that NxStage Medical will post ($0.05) earnings per share for the current fiscal year.

Several brokerages recently issued reports on NXTM. Jefferies Group LLC cut shares of NxStage Medical from a “buy” rating to a “hold” rating and reduced their price target for the company from $33.00 to $30.00 in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Thursday, August 10th. BTIG Research cut shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday, August 11th. Northland Securities reiterated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research report on Monday, August 7th. Finally, Canaccord Genuity cut shares of NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target on the stock. in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.25.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact NxStage Medical (NXTM) Share Price” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-nxstage-medical-nxtm-share-price/1554604.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total transaction of $25,190.00. Following the sale, the president now owns 75,903 shares of the company’s stock, valued at approximately $1,911,996.57. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $23.14, for a total transaction of $80,990.00. Following the sale, the senior vice president now directly owns 17,270 shares in the company, valued at approximately $399,627.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,900 shares of company stock worth $1,491,266. Insiders own 4.70% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.